Loading
The validation of Thermo Fisher's tissue sequencing test, which reads DNA and RNA from the same small sample.
In 462 fixed tumour samples, agreement with orthogonal methods for RNA variants (fusions and splice variants) was 95.9 per cent positive and 100 per cent negative; RNA repeatability ranged from 88.9 per cent (ALK fusion) to 100 per cent.
Approved tissue tests now read RNA fusions alongside DNA in one run.
Shares Companion diagnostics, RNA sequencing & expression profiling.
Shares Companion diagnostics, RNA sequencing & expression profiling.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/